Mary E. Hamby
Cognition Therapeutics (United States) · 50 works · 2,611 citations · h-index 19
Top works
- To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers
- Reactive Astrocytes As Therapeutic Targets for CNS Disorders
- Dopaminergic Cell Loss Induced by Human A30P α -Synuclein Gene Transfer to the Rat Substantia Nigra
- Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain
- Neuroprotection mediated through estrogen receptor-α in astrocytes
- Inflammatory Mediators Alter the Astrocyte Transcriptome and Calcium Signaling Elicited by Multiple G-Protein-Coupled Receptors
- The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer’s Disease
- Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes
- TGF‐β1 potentiates astrocytic nitric oxide production by expanding the population of astrocytes that express NOS‐2
- Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain
- Smad3‐dependent signaling underlies the TGF‐β1‐mediated enhancement in astrocytic iNOS expression
- Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
- Transcriptional regulation of neuronal differentiation: The epigenetic layer of complexity
- Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
- Generation of Primary Astrocyte Cultures Devoid of Contaminating Microglia
- Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
- TGFβ1 and TNFα potentiate nitric oxide production in astrocyte cultures by recruiting distinct subpopulations of cells to express NOS-2
- A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
- A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter
- TGF-β1 reduces the heterogeneity of astrocytic cyclooxygenase-2 and nitric oxide synthase-2 gene expression in a stimulus-independent manner